Lloyd Price
- Feb 18

Ozempic, WeGovy, Trulicity: How GLP-1s influence Pharma and HealthTech shares

Exec Summary:

GLP-1 receptor agonists, also known as GLP-1s, had a significant impact on the healthtech stock market in 2023, driving growth and shaping investor sentiment. Here's a breakdown of their influence:

Positive impacts:

Rising demand for diabetes treatments: GLP-1s emerged as a popular treatment option for type 2 diabetes, offering improved glycemic control and potential cardiovascular benefits. This growing demand fuelled stock prices of companies developing and manufacturing GLP-1s, such as Novo Nordisk, Eli Lilly, and Boehringer Ingelheim.
Expanding applications: Research on GLP-1s revealed potential benefits beyond diabetes, including weight management, obesity treatment, and even neurodegenerative diseases. This broadened the market potential for GLP-1s, attracting further investment and boosting stock prices of companies involved in this research.
Mergers and acquisitions: The promising future of GLP-1s led to several mergers and acquisitions within the healthtech industry. These deals aimed to consolidate market share, expand research capabilities, and accelerate product development, further stimulating investor interest.

Challenges and considerations:

Patent expirations: Looming patent expirations for some early GLP-1 drugs posed a challenge for their manufacturers' stock prices. Companies had to focus on innovation and diversification to maintain market share and investor confidence.
Regulatory hurdles: The approval process for new GLP-1 indications can be lengthy and complex, creating uncertainty for investors. Companies needed to navigate these hurdles effectively to ensure timely product launches and maintain stock performance.
Competition: The GLP-1 market is becoming increasingly competitive, with new players entering the field and established players developing rival drugs. This competition can put pressure on stock prices as companies vie for market share.

Overall, GLP-1s had a positive influence on the healthtech stock market in 2023, driving growth and shaping investor sentiment. However, the market is not without its challenges, and companies need to be strategic in their approach to innovation, regulatory affairs, and competition to maintain their position.

Corporate Development for Healthcare Technology companies in EMEA

Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital

HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk

HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb

HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

History of GLP-1s

The history of GLP-1s is a fascinating journey spanning decades, fuelled by scientific curiosity and a desire to improve human health. Here's a glimpse into its timeline:

Early Discoveries (1970s-1980s):

1970s: Discovery of the "incretin effect," where gut hormones boost insulin secretion after meals.
1982: Identification of GLP-1, one of the key incretin hormones, extracted from the intestines.
1987: Confirmation of GLP-1's potent ability to stimulate insulin release and lower blood sugar.

Understanding and Development (1990s-2000s):

1990s: Research delves into the GLP-1 receptor and its role in regulating metabolism.
1996: Studies suggest GLP-1's potential in managing type 2 diabetes and obesity.
2004: First GLP-1 receptor agonist (GLP-1 RA), exenatide, approved for type 2 diabetes treatment.
2005: Liraglutide, another GLP-1 RA, joins the scene, offering longer-lasting action.

Evolution and Expansion (2010s-Present):

2010s: New GLP-1 RAs with diverse formulations (injections, tablets) and extended durations emerge.
2014: Liraglutide becomes the first GLP-1 RA approved for weight management.
2020s: Research expands beyond diabetes and obesity, exploring potential benefits in cardiovascular health, Alzheimer's disease, and more.
Today: GLP-1 RAs are a mainstay in diabetes and obesity management, with ongoing research exploring their broader therapeutic potential.

Key Milestones and Players:

Early discoveries: Scientists like Jørgen Holst, Jens Juul Holst, and Daniel Drucker played crucial roles in identifying and characterizing GLP-1.
Drug development: Pharmaceutical companies like Novo Nordisk, Eli Lilly, and AstraZeneca led the development and commercialization of GLP-1 RAs.
Clinical trials: Large-scale clinical trials established the efficacy and safety of GLP-1 RAs, paving the way for their widespread use.

Looking Ahead:

The story of GLP-1s is still unfolding. With ongoing research and development, we can expect to see:

More diverse GLP-1 RAs: Tailored to specific patient needs and preferences.
Combination therapies: GLP-1 RAs combined with other drugs for enhanced efficacy.
New therapeutic applications: Expanding beyond diabetes and obesity to address other health conditions.

The journey of GLP-1s highlights the power of scientific exploration and its potential to revolutionise healthcare. As research continues, this remarkable molecule holds the promise of further improving human health and well-being.

Image Source: https://ro.co/weight-loss/potential-ripple-effect-of-glp1s/

How did GLP-1s impact the stock market in 2023?

GLP-1s, particularly those approved for weight management, had a significant impact on the stock market in 2023, but it was a complex and multifaceted effect:

Positive Impact:

Pharmaceutical companies developing and selling GLP-1s: Companies like Novo Nordisk and Eli Lilly saw significant stock price increases due to the enormous demand for their products, particularly Wegovy and Mounjaro.
Obesity-related treatment companies: Some companies offering non-GLP-1 obesity treatments, like bariatric surgery or medical devices, experienced initial stock gains due to the increased awareness of obesity solutions.

Negative Impact:

Food and Beverage companies: The appetite-suppressing effects of GLP-1s led to concerns about reduced food consumption, impacting the stock prices of companies in this sector, with some experiencing significant declines.

Medtech companies: The potential of GLP-1s to replace or reduce the need for certain medical devices for obesity-related conditions caused stock price drops for companies in this sector.

Companies reliant on traditional obesity treatments: Some companies offering weight loss medications or programs not involving GLP-1s faced challenges as GLP-1s gained popularity, impacting their stock prices.

Overall:

The impact was not uniform, with winners and losers depending on their specific product offerings and potential disruption by GLP-1s.
The market dynamics were complex, influenced by various factors beyond just the direct impact of GLP-1s.
The long-term impact of GLP-1s on the stock market remains to be seen, as the technology continues to evolve and its applications expand.

How will GLP-1s potentially affect HealthTech share prices in 2024?

The potential impact of GLP-1s on HealthTech share prices in 2024 is a complex and multifaceted issue, with both positive and negative possibilities. Here's a breakdown of the key factors to consider:

Potential Negative Impacts:

Reduced Demand for Certain Devices: GLP-1s can lead to weight loss, potentially reducing the need for some medical devices like gastric bands or balloons used for weight management. This could negatively impact companies specialising in these devices.
Shifting Focus from Procedures to Pharmaceuticals: As GLP-1s become more popular, the focus might shift from invasive procedures like bariatric surgery towards medication-based treatment, potentially impacting companies reliant on these procedures.
Investor Uncertainty and Fear: The potential disruption caused by GLP-1s has already led to investor concerns and sell-offs in some medtech stocks. This sentiment might persist in 2024, further impacting share prices.

Potential Positive Impacts:

Complementary Solutions: GLP-1s might not entirely replace existing medtech solutions but rather complement them, offering patients a broader range of treatment options. This could benefit companies offering devices for monitoring or managing diabetes or other conditions alongside GLP-1 therapy.
New Opportunities in Diagnostics and Monitoring: As GLP-1 use expands, the need for accurate diagnosis, personalised treatment plans, and patient monitoring might increase, creating new opportunities for medtech companies developing relevant tools and technologies.
Innovation and Adaptation: The medtech industry is known for its adaptability and innovation. Companies might develop new devices and technologies specifically designed to work alongside GLP-1s, potentially mitigating the negative impacts and creating new revenue streams.